KOSDAQFood & Beverage194700

Novarex

₩8,100▲ 1.00%2026-11-18 close
Market Cap
₩147.9B
Turnover
₩200M
Volume
20K
Shares out.
18.3M
PER
5.3×
PBR
0.6×
EPS
₩1,624
Dividend Yield
4.67%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩400 per share · Prices as of the 2026-11-18 close

01

Report overview

Novarex: Q3 2026 Swings to Net Loss After Record Q1

Novarex's earnings recovered in 2025, but sales and operating profit have declined for two consecutive quarters since the first quarter of 2026, and the third quarter of 2026 turned to a net loss attributable to controlling shareholders of KRW 1.9 billion. The completion of the Osong No. 2 plant is the next checkpoint.

  1. 1

    Full-year 2025 sales rose 35.8% to KRW 404.3 billion, and operating profit rose 85.6% to KRW 43.1 billion.

  2. 2

    Quarterly sales peaked at KRW 120.8 billion in the first quarter of 2026 and then fell for two consecutive quarters.

  3. 3

    In the third quarter of 2026, operating profit was KRW 6.55 billion and the company posted a net loss attributable to controlling shareholders of KRW 1.9 billion.

  4. 4

    Net income attributable to controlling shareholders for the last four quarters totals KRW 28.8 billion, below the KRW 35.4 billion recorded for full-year 2025.

  5. 5

    The company said that once the Osong No. 2 plant is completed in the second half of 2027, annual capacity would roughly double from about KRW 500 billion to KRW 1 trillion.

02

Business structure

Novarex is a health functional food ODM and OEM manufacturer founded in November 2008 and listed on KOSDAQ in November 2018. The company positions its holding of one of the largest sets of individually recognized raw materials in Korea as the foundation of its competitiveness.

In formulation technology it highlights sustained-release tablet technology and its 'Switchu' formulation technology.

Sales are split between domestic and overseas, and according to company figures released for the first quarter of 2026, domestic sales were KRW 77.3 billion, up 30.4% year on year, while overseas sales were KRW 43.5 billion, up 38.5%.

Domestically, DS Investment attributed the rise in customer orders to a broader health functional food lineup at new distribution channels such as Olive Young and convenience stores. Overseas, growth factors include higher sales of Vitapack and fish oil products in China and expanding exports to Asia.

The company said it is developing new customers in China while widening cooperation in the United States, Europe, and the Middle East and halal markets. On competition, the company points to its speed in proposing formulations and blends and its quality control capabilities.

On the production side, it is pairing line efficiency investment at its existing No. 1 plant with the construction of a new Osong No. 2 plant, which has already broken ground. Quarterly sales are influenced by the structure of ODM work, where volumes move with customer orders.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩113.8B₩12.9B11.3%
2025Q4₩100.7B₩10.7B10.6%
2026Q1₩120.8B₩14.1B11.7%
2026Q2₩101.8B₩11B10.8%
2026Q3₩92.5B₩6.6B7.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩281.7B₩25.2B₩20B8.9%11.0%49.2%
2023₩302.2B₩25.5B₩22B8.4%11.0%32.1%
2024₩297.7B₩23.2B₩23B7.8%10.5%31.5%
2025₩404.3B₩43.1B₩35.4B10.6%14.0%41.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales moved from KRW 281.7 billion in 2022 to KRW 302.2 billion in 2023 (up 7.3%) and KRW 297.7 billion in 2024 (down 1.5%), before reaching KRW 404.3 billion in 2025 (up 35.8%), the largest year in the 2022 to 2025 period.

Operating profit was KRW 25.2 billion in 2022, KRW 25.5 billion in 2023 (up 1.2%), KRW 23.2 billion in 2024 (down 9.1%), and KRW 43.1 billion in 2025 (up 85.6%), with 2024 the smallest year.

Operating margin fell from 8.9% in 2022 to 7.8% in 2024 before rising to 10.6% in 2025, so the profit recovery outpaced sales growth. Net income attributable to controlling shareholders rose for three consecutive years from 2023 through 2025, reaching KRW 35.4 billion in 2025, up 53.9%.

Net income including non-controlling interests was KRW 36 billion in 2025, close to the controlling-shareholder figure. Operating cash flow rose from KRW 13.3 billion in 2024 to KRW 16.7 billion in 2025 but remained below KRW 25.3 billion in 2023 and below 2025 net income.

The debt-to-equity ratio climbed from 31.5% in 2024 to 41.2% in 2025, with total liabilities of KRW 104.9 billion and total equity of KRW 254.6 billion at year-end 2025.

Quarterly sales went from KRW 113.8 billion in the third quarter of 2025 to KRW 100.7 billion in the fourth quarter (down 11.6% quarter on quarter), then peaked at KRW 120.8 billion in the first quarter of 2026 (up 20.0%).

Sales then fell to KRW 101.8 billion in the second quarter (down 15.7%) and KRW 92.5 billion in the third quarter (down 9.1% quarter on quarter and down 18.7% year on year), marking two consecutive quarterly declines.

Operating profit went from KRW 14.1 billion in the first quarter of 2026 to KRW 11 billion in the second quarter and KRW 6.55 billion in the third quarter (down 49.3% year on year).

Net income attributable to controlling shareholders moved from KRW 14.6 billion in the first quarter of 2026 to KRW 7.67 billion in the second quarter, then turned to a net loss of KRW 1.9 billion in the third quarter.

The company announced preliminary first-half 2026 sales of KRW 222.6 billion (up 17.3%) and operating profit of KRW 25.1 billion (up 29.2%) on August 14, 2026. Whether the third-quarter swing to a loss stemmed from one-off items or operating factors cannot be separated from the disclosed figures alone.

05

Industry analysis

Expectations for the health functional food market rest on rising elderly population and growing health awareness. On distribution, new channels such as convenience stores and Olive Young are widening health functional food lineups, which has increased customer orders for ODM suppliers.

On products, the company stresses that faster shifts in consumer trends have made the speed of formulation and blend development a competitive factor. In a May 2026 report, DS Investment said Novarex's plant utilization in the first quarter of 2026 was 113% and had been above 100% since the second half of last year.

Utilization above 100% points to a need for capacity expansion, which the company is addressing through the new Osong No. 2 plant alongside line efficiency work at the No. 1 plant. DS Investment noted that domestic sales of KRW 77.3 billion in the first quarter of 2026 were the highest quarterly level on record.

Overseas, DS Investment judged that the export slowdown it had worried about was a matter of timing, but sales fell in the second and third quarters, so the durability of overseas momentum is a point to confirm in upcoming quarterly results.

Relative positioning against peers can be described around the company's holding of individually recognized raw materials and its formulation technology.

Within the food sector, DS Investment said it lowered its target multiple from 12 times to 10 times, the same as peers, to reflect a decline in the sector's relative attractiveness. New customer development in China and cooperation in the Middle East and halal markets could spread export exposure across more channels.

06

Outlook

On August 14, 2026, the company announced preliminary first-half results and said it will continue expanding production infrastructure, widening global customer access, and strengthening formulation technology in the second half.

In May 2026, the company said the Osong No. 2 plant had broken ground and that annual capacity would roughly double from about KRW 500 billion to KRW 1 trillion once it is completed in the second half of 2027.

In the same period, DS Investment projected 2026 sales of KRW 481.6 billion (up 19%), operating profit of KRW 54.2 billion (up 26%), and an operating margin of 11.3%.

Disclosed sales for the first three quarters of 2026 add up to KRW 315.1 billion and operating profit to KRW 31.65 billion, so reaching that projection would require fourth-quarter sales of KRW 166.5 billion and operating profit of KRW 22.55 billion.

The gap is tied to the fact that the projection was made in May 2026, so whether it has been revised is the next point to confirm. On shareholder returns, the company carried out a share cancellation at the end of March 2026 and said it would keep expanding shareholder-friendly policies.

On exports, the question is how far new customers in China and cooperation in the United States, Europe, and the Middle East and halal markets feed into sales after the second half of 2026.

On finances, the key checkpoint is how far the KRW 104.9 billion in total liabilities at year-end 2025 grows with capacity investment. Once the 2026 annual report discloses fourth-quarter results and full-year operating margin, the gap between the projection and actual results will be clearer.

07

Valuation

PER
5.3×
PBR
0.6×
ROE
11.3%
EPS
₩1,624
BPS
₩15,002
Dividend per share
₩400

Price-to-book (PBR) is trading in a range below 1 times. According to the 5-year figures compiled by Value Line in September 2026, the PBR averaged 1.30 times and the PER averaged 9.65 times, and current multiples sit below those levels.

The lower multiples reflect falling earnings, since the last four quarters' net income attributable to controlling shareholders totals KRW 28.8 billion, below the KRW 35.4 billion for 2025, and includes a third-quarter net loss.

Earnings-based multiples can swing sharply with quarterly results, so one or two quarters alone are hard to interpret.

Of the KRW 254.6 billion in total equity at year-end 2025, KRW 253.1 billion belongs to controlling shareholders, and the debt-to-equity ratio rising from 31.5% in 2024 to 41.2% in 2025 changes how the capital structure should be read.

In a May 2026 report, DS Investment said it raised its target price to KRW 26,000 and lowered its target multiple from 12 times to 10 times to reflect lower relative attractiveness of the food sector.

The company has paid dividends every year, and in late March 2026 a share cancellation was added as a shareholder return measure.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Quarterly peak and profit recovery

Quarterly sales peaked at KRW 120.8 billion and operating profit at KRW 14.1 billion in the first quarter of 2026, the highest in the disclosed quarterly series. The company described this as its record quarterly result when it announced the figures on May 15, 2026. Full-year 2025 operating profit rose 85.6% to KRW 43.1 billion, a sizable recovery.

Overseas sales and customer diversification

The company said in May 2026 that first-quarter 2026 overseas sales rose 38.5% year on year to KRW 43.5 billion. It is developing new customers in China and widening cooperation in the United States, Europe, and the Middle East and halal markets. Preliminary first-half 2026 sales of KRW 222.6 billion, up 17.3%, were announced on August 14, 2026.

Capacity expansion and shareholder returns

The company said the Osong No. 2 plant has broken ground and that annual capacity would double once it is completed in the second half of 2027. DS Investment reported that plant utilization in the first quarter of 2026 was 113%.

The company also carried out a share cancellation at the end of March 2026 as part of its shareholder value activities.

09

Bear factors

Consecutive quarterly declines

Second-quarter 2026 sales of KRW 101.8 billion fell 15.7% from the prior quarter, and third-quarter sales of KRW 92.5 billion fell 18.7% year on year. Third-quarter operating profit of KRW 6.55 billion was down 49.3% year on year. Net income attributable to controlling shareholders swung to a net loss of KRW 1.9 billion.

Cash flow and debt burden

Operating cash flow in 2025 was KRW 16.7 billion, below net income of KRW 36 billion. The debt-to-equity ratio rose from 31.5% in 2024 to 41.2% in 2025, with total liabilities of KRW 104.9 billion. If capacity investment continues, the burden on this cash flow could become more visible.

Gap between projection and results

A large gap exists between the KRW 481.6 billion full-year 2026 sales projection DS Investment presented in May 2026 and the KRW 315.1 billion disclosed for the first three quarters combined. Because the projection dates from May 2026, it is not yet clear whether the subsequent quarterly trend has been reflected in it.

DS Investment's view that the export slowdown was a timing issue was tested by the sales decline in the third quarter.

10

Risk factors

Demand and order volatility

Because quarterly sales move with customer order volumes, a drop in orders as in the second and third quarters of 2026 can reduce profit quickly. Third-quarter operating profit fell 49.3% year on year.

Whether the order swings reflect channel restructuring or temporary adjustments cannot be separated from the disclosures alone.

Capex and completion timing

The company plans to complete the Osong No. 2 plant in the second half of 2027, while DS Investment projects capacity of KRW 800 billion to KRW 1 trillion by the end of 2027, so timing and scale differ. A delay would prolong pressure on a plant running at 113% utilization and could cost orders. During the investment period, the debt ratio and cash flow may come under strain.

Overseas exposure and regulation

Overseas sales of KRW 43.5 billion in the first quarter of 2026 accounted for roughly a third of total sales. Export flows can shift with overseas customer orders, country-specific rules, and currency movements. Because health functional food regulation differs by country, it affects the pace of entry into new markets.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will finalize fourth-quarter results, full-year operating margin, and operating cash flow. Comparing these with the disclosed first-to-third-quarter totals shows how closely the fourth quarter tracked the projection.

  2. Around mid-May 2027 (expected)

    This is the first-quarter 2027 earnings release. The first quarter of 2026 was announced on May 15. Key checks are whether operating profit recovers from the KRW 6.55 billion level of the third quarter of 2026 and whether overseas sales keep growing.

  3. Second half of 2027

    Completion of the Osong No. 2 plant and expansion of annual capacity. The company's timeline points to the second half of 2027, while DS Investment's projection points to the end of 2027, so the difference in timing needs to be tracked.

12

Overall view

Novarex grew scale in 2025, with sales of KRW 404.3 billion and operating profit of KRW 43.1 billion, and its operating margin recovered to 10.6%.

However, sales peaked at KRW 120.8 billion in the first quarter of 2026 and then declined in the second and third quarters, and in the third quarter operating profit fell to KRW 6.55 billion and the company posted a net loss attributable to controlling shareholders of KRW 1.9 billion.

Bullish factors include strong overseas growth, new customers in China and the Middle East, and a plan to double production capacity. Bearish factors include consecutive quarterly declines, a rising debt-to-equity ratio, and operating cash flow trailing net income.

The gap between DS Investment's May 2026 projection and the disclosed first-to-third-quarter totals leaves the projection versus actual results as an open issue. Valuation sits with price-to-book below 1 times, but the swing to a loss widens the range of interpretation for earnings-based multiples.

The next checkpoints are the 2026 annual report, the first-quarter 2027 results, and completion of the Osong No. 2 plant.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. kokstock.com
  2. valueline.co.kr
  3. investing.com
  4. thevc.kr
  5. kr.tradingview.com
  6. markets.hankyung.com
  7. valueline.co.kr
  8. eugenefn.com
  9. ftoday.co.kr
  10. ftoday.co.kr
  11. investing.com
  12. v.daum.net
  13. mt.co.kr
  14. newspim.com
  15. supple.kr
  16. comp.wisereport.co.kr
  17. srtimes.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis